These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

303 related items for PubMed ID: 3366469

  • 21. On the mechanism of cell membrane damage by complement: evidence on insertion of polypeptide chains from C8 and C9 into the lipid bilayer of erythrocytes.
    Hammer CH, Shin ML, Abramovitz AS, Mayer MM.
    J Immunol; 1977 Jul; 119(1):1-8. PubMed ID: 559700
    [Abstract] [Full Text] [Related]

  • 22. Mapping of the complement C9 binding domain in paramyosin of the blood fluke Schistosoma mansoni.
    Deng J, Gold D, LoVerde PT, Fishelson Z.
    Int J Parasitol; 2007 Jan; 37(1):67-75. PubMed ID: 17123534
    [Abstract] [Full Text] [Related]

  • 23. Complement S-protein (vitronectin) is associated with cytolytic membrane-bound C5b-9 complexes.
    Bhakdi S, Käflein R, Halstensen TS, Hugo F, Preissner KT, Mollnes TE.
    Clin Exp Immunol; 1988 Dec; 74(3):459-64. PubMed ID: 2466593
    [Abstract] [Full Text] [Related]

  • 24. C5b-9 assembly: average binding of one C9 molecule to C5b-8 without poly-C9 formation generates a stable transmembrane pore.
    Bhakdi S, Tranum-Jensen J.
    J Immunol; 1986 Apr 15; 136(8):2999-3005. PubMed ID: 3958488
    [Abstract] [Full Text] [Related]

  • 25. Isolation of homologous restriction factor from human urine. Immunochemical properties and biologic activity.
    Zalman LS, Brothers MA, Müller-Eberhard HJ.
    J Immunol; 1989 Sep 15; 143(6):1943-7. PubMed ID: 2476489
    [Abstract] [Full Text] [Related]

  • 26. Species-restricted target cell lysis by human complement: complement-lysed erythrocytes from heterologous and homologous species differ in their ratio of bound to inserted C9.
    Hu VW, Shin ML.
    J Immunol; 1984 Oct 15; 133(4):2133-7. PubMed ID: 6470486
    [Abstract] [Full Text] [Related]

  • 27. Anti-idiotypic antibodies derived against C8, C9 and perforin bind homologous restriction factor.
    Young JD, Jiang S, Liu CC, Hasselkus-Light CS.
    J Immunol Methods; 1990 Mar 27; 128(1):133-42. PubMed ID: 1691232
    [Abstract] [Full Text] [Related]

  • 28. Membrane vesiculation protects erythrocytes from destruction by complement.
    Iida K, Whitlow MB, Nussenzweig V.
    J Immunol; 1991 Oct 15; 147(8):2638-42. PubMed ID: 1918984
    [Abstract] [Full Text] [Related]

  • 29. The attack phase of human complement: differentiation between membrane binding and complex formation by the detection of neoantigen expression in situ. A morphometric immunoferritin study.
    Balkarowa-Ständer J, Rother U, Rauterberg EW.
    J Immunol; 1981 Sep 15; 127(3):1089-93. PubMed ID: 7264298
    [Abstract] [Full Text] [Related]

  • 30. Clusterin, the human apolipoprotein and complement inhibitor, binds to complement C7, C8 beta, and the b domain of C9.
    Tschopp J, Chonn A, Hertig S, French LE.
    J Immunol; 1993 Aug 15; 151(4):2159-65. PubMed ID: 8345200
    [Abstract] [Full Text] [Related]

  • 31. Lytic activity of C5-9 complexes for erythrocytes from the species other than sheep: C9 rather than C8-dependent variation in lytic activity.
    Yamamoto KI.
    J Immunol; 1977 Oct 15; 119(4):1482-5. PubMed ID: 894048
    [Abstract] [Full Text] [Related]

  • 32. Homologous species restriction of the complement-mediated killing of nucleated cells.
    Yamamoto H, Blaas P, Nicholson-Weller A, Hänsch GM.
    Immunology; 1990 Aug 15; 70(4):422-6. PubMed ID: 1697561
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Deviated lysis: transfer of complement lytic activity to unsensitized cells. IV. Parital isolation of the activity.
    Hänsch G, Rother U, Rother K.
    Z Immunitatsforsch Immunobiol; 1977 Apr 15; 153(1):48-59. PubMed ID: 868206
    [Abstract] [Full Text] [Related]

  • 35. The homologous restriction factor is immunologically related to complement components C8 and C9 and to lymphocyte pore-forming protein perforin through cysteine-rich domains.
    Young JD, Rosse WF, Hasselkus-Light CS.
    Biochem Biophys Res Commun; 1990 Jan 30; 166(2):648-52. PubMed ID: 2302230
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Studies of the association of the eighth and ninth components of human complement within the membrane-bound cytolytic complex.
    Monahan JB, Stewart JL, Sodetz JM.
    J Biol Chem; 1983 Apr 25; 258(8):5056-62. PubMed ID: 6833292
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Binding of human and rat CD59 to the terminal complement complexes.
    Lehto T, Morgan BP, Meri S.
    Immunology; 1997 Jan 25; 90(1):121-8. PubMed ID: 9038722
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.